Malignant Melanotic Nerve Sheath Tumor

J.C. Benson, M.D. Marais, P.M. Flanigan, M. Bydon, C. Giannini, R.J. Spinner and A.L. Folpe

AJNR Am J Neuroradiol  published online 27 October 2022
http://www.ajnr.org/content/early/2022/10/27/ajnr.A7691

This information is current as of July 31, 2024.
Malignant Melanotic Nerve Sheath Tumor

J.C. Benson, M.D. Marais, P.M. Flanigan, M. Bydon, C. Giannini, R.J. Spinner, and A.L. Folpe

ABSTRACT

SUMMARY: Malignant melanotic nerve sheath tumors are uncommon pigmented tumors of Schwann cell origin, most often found along the spinal nerves. Although well-described in the literature, the tumors are quite rare, making up <1% of nerve sheath tumors. Physicians are, therefore, often unfamiliar with both the appearance and the optimal treatment of such tumors. Morphologically, many imaging features overlap with schwannomas and neurofibromas. Nevertheless, the malignant melanotic nerve sheath tumors are crucial to identify. They can be extremely aggressive, and the management of these tumors is considerably different from their benign counterparts. In this radiology-pathology review, we will highlight the imaging appearance, histologic features, surgical resection, and subsequent therapeutic strategies in a patient with a lumbar malignant melanotic nerve sheath tumor.

ABBREVIATION: MMNST = malignant melanotic nerve sheath tumor

The patient is a 39-year-old woman with no notable medical history who presented with a 5-year history of progressive left, lower-extremity, radicular symptoms. Her symptoms began as intermittent pain in her left leg, which evolved into constant pain and dysesthesias. On physical examination, she demonstrated mild weakness of left toe extension and trace weakness of left ankle inversion/eversion. An initial lumbar spine MR imaging performed at an outside institution 4 years prior to presentation was interpreted as having normal findings. Follow-up imaging, performed 1 year before presentation, identified a mass along the L5 nerve root. In retrospect, this had been present on the first examination and had grown in the interim. The patient presented to our institution for further management.

Imaging

MR imaging of the lumbar spine demonstrated an elongated well-circumscribed mass centered in the left L5-S1 foramen with both intra- and extradural components. The mass extended centrally to the left lateral recess and peripherally into the extraforaminal space along the exiting nerve root. There was no remodeling of the adjacent bone. Intratumoral signal was homogeneously hyperintense on T1 and hypointense on T2 (Fig 1). Homogeneous enhancement was observed on postcontrast images. Comparison with prior imaging demonstrated progressive growth of the tumor during the course of the prior MRIs, from 1.0 to 1.6 cm in maximum axial diameter during a 4-year period. Because of its imaging characteristics, the mass was thought most likely to represent a malignant melanotic nerve sheath tumor. A melanin-containing metastasis was also considered possible, though less likely given the patient’s negative medical history. A benign hemorrhagic nerve sheath tumor was thought to be unlikely, given its homogeneous intraleSIONal signal and consistent appearance across time.

Imaging findings of the brain and cervical and thoracic spine were normal, without evidence of leptomeningeal metastases.

Operative Report

Given the patient’s steadily worsening radicular symptoms, mild weakness on examination, and the uncertain malignant potential of the mass, surgical treatment was recommended. The tumoral resection required an L5 laminectomy and a complete left L5-S1 facetectomy due to the extensive involvement of the mass along the nerve (from the nerve root axilla to the extraforaminal segment of the left L5 nerve, even extending underneath the sacral ala). Intraoperatively, after the above bony elements had been removed, the melanotic-appearing spinal nerve was identified along its course by careful dissection of overlying soft tissues. Neuromonitoring was used to enhance intraoperative understanding of regional anatomy. Despite appropriate firing of other nerves in the operative field, a firing response was not able to be elicited, suggesting the nerve was nonfunctional from a motor standpoint.

Received August 15, 2022; accepted after revision September 30.

From the Departments of Radiology (J.C.B., M.D.M.), Neurologic Surgery (P.M.F., M.B.), and Laboratory Medicine and Pathology (C.G., R.J.S., A.L.F.), Mayo Clinic, Rochester, Minnesota.

Please address correspondence to John C. Benson, MD, Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55902; e-mail: benson.john3@mayo.edu

http://dx.doi.org/10.3174/ajnr.A7691

Published October 27, 2022 as 10.3174/ajnr.A7691

Copyright 2022 by American Society of Neuroradiology.
Under the microscope, the multilobular tumor was separated from the nerve using standard microsurgical dissection techniques. After identifying the most distal aspect of the tumor, a dissection plane was made between it and the nerve, proceeding in a distal-to-proximal direction. At its proximal extent, a small portion of intradural tumor extension was encountered and, consequently, CSF egress occurred from that site. The spinal fluid leak ultimately was repaired satisfactorily. A substantial majority of the mass was removed en bloc (Fig 2), and there was no trace of residual tumor seen grossly. The patient awoke at the neurologic baseline and had an uneventful postoperative course.

**Pathology**

Grossly, the tumor appeared as a jet-black, multinodular, fusiform expansion of the nerve root, measuring 4.5 cm in greatest dimension. Microscopically, the tumor cells were predominantly epithelioid in morphology, with abundant intracytoplasmic melanin pigment and variably-sized nuclei with prominent nucleoli; mitotic activity was <1/50 high-powered fields; and necrosis was absent (Fig 2). By immunohistochemistry, the neoplastic cells showed diffuse expression of S-100 protein and Melan-A with complete loss of PRKARIA, an immunophenotype diagnosis of malignant melanotic nerve sheath tumor (MMNST) in this clinical and morphologic context. Loss of PRKARIA expression is commonly seen in MMNST and is not a feature of conventional malignant melanoma or melanoma arising in a cellular blue nevus, melanocytic tumors that share some morphologic and immunohistochemical features with MMNST. Although molecular genetic studies were not needed in the present case, MMNST also differed genetically from other malignant melanotic tumors, with MMNST having PRKARIA mutations; conventional melanomas showing mutations in BRAF, NRAS or KRAS; and melanoma arising in a blue nevus containing mutations in the GNA genes.

**DISCUSSION**

MMNSTs are pigmented tumors often located in the spine and paraspinal soft tissues. Formerly known as melanotic schwannomas, these tumors were reclassified in 2020 to reflect their aggressive clinical behavior. MMNSTs are rare, making up <1% of all nerve sheath tumors. The tumors tend to occur in the fourth decade of life without a sex predilection. Although MMNSTs can occur along cranial nerves, they tend to grow along the dorsal spinal nerve roots, and patients often present with indolent pain, weakness, or paresthesia along a corresponding dermatome. Tumors may also be discovered incidentally on spinal imaging. Although acute presentations have been described in MMNSTs, these reports are rare.

On imaging, spinal MMNSTs generally appear similar to the appearance presented in the current case: intradural, extramedullary tumors. In the spine, the tumors typically grow along spinal nerve roots, sometimes assuming a dumbbell configuration if they extend through a foramen. Tumors demonstrate enhancement on CT and are FDG-avid on PET. Paramagnetic free radicals associated with the intratumoral melanin give the tumors a distinctive T1-hyperintense and T2-hypointense appearance. This feature is inconstant; 1 review found that only 65% of tumors demonstrated T1 hyperintensity, likely reflecting the variable concentrations of intratumoral melanin and cellular densities of tumors. Intratumoral T2 hyperintensity, too, is variable. In very rare cases, the tumors may arise from within...
the spinal cord.\textsuperscript{14-16} No imaging features have been identified to serve as prognostic markers to predict the aggressiveness of the tumor.\textsuperscript{8}

The major differential considerations for MMNSTs are those of other intradural, extramedullary tumors closely related to spinal nerves. The most likely entities would be benign schwannomas and neurofibromas, meningoïd, malignant peripheral nerve sheath tumors, or metastases. On CT, distinguishing these tumors may be impossible. The “dumbbell” morphology, for instance, is nonspecific; all of these tumors can take this shape if they contain both intradural and extradural components.\textsuperscript{17} On MR imaging, however, the intrinsic T1 hypointensity associated with MMNSTs can be used to distinguish such tumors from their mimics. Schwannomas and neurofibromas tend to be hypointense on T1 and hyperintense on T2. Larger schwannomas, in particular, can be markedly T2 hyperintense and even demonstrate ringlike enhancement because they often undergo cystic degeneration.\textsuperscript{18} Nevertheless, T1 hyperintensity can also be seen in the setting of meningeal melanotic neoplasms and melanoma metastases, both of which could be included as differential considerations on imaging.\textsuperscript{19}

The management of patients with MMNSTs can be complex. The tumors are capable of substantial malignant spread, with local recurrence found in more than one-third of patients, and metastatic disease, in 44% of cases.\textsuperscript{1} Lungs are the most common site of metastases, though many other sites have been reported.\textsuperscript{20-22} Some tumors can lead to considerable leptomeningeal spread.\textsuperscript{23} MMNSTs are known to recur or spread after 5 years, even without sinister histologic markers.\textsuperscript{9}

Furthermore, the tumors are associated with the Carney complex, an autosomal dominant syndrome characterized by cardiac and extracardiac myxomas, spotty skin pigmentation, endocrine overactivity, and testicular tumors.\textsuperscript{24} The precise association between MMNSTs and Carney complex has been a matter of debate. Carney\textsuperscript{25} reported that one-half of patients with MMNSTs containing psammoma bodies (previously called “psammatous melanotic schwannomas”) had Carney complex features. Others, most notably Torres-Mora et al.,\textsuperscript{1} found no clinicopathologic differences between psammomatous and nonpsammomatous malignant schwannomas, and they have doubted that any distinction exists between these tumor subtypes and their associations with Carney complex.

Surgical resection is the mainstay of treatment, with gross total resection recommended.\textsuperscript{26} Adjuvant therapy and management of metastatic or recidivist disease, however, are less well-defined, given the scarcity of MMNSTs. Some authors suggest adjuvant radiation therapy following resection that did not accomplish clear surgical margins, though the evidence for this remains mostly anecdotal in the literature.\textsuperscript{6,27,28} The patient presented in this case is expected to have a favorable postoperative course. His most recent imaging, performed 4 months after the operation, showed no evidence of residual or recurrent tumor. He will be assessed by radiation oncology to consider adjuvant treatment and will undergo surveillance imaging to rule out recidivist disease.

**Case Summary**

- Although rare, MMNSTs are crucial to identify on imaging because they are aggressive and prone to metastasizing.

- On MRI, MMNSTs demonstrate characteristic T1 hyperintensity and T2 hyperintensity related to intratumoral melanin.

- Characteristic morphologic features and loss of \textit{PRKAR1A} expression help to distinguish MMNSTs from morphologic mimics, in particular metastatic melanoma and melanoma arising from a cellular blue nevus.

- Surgical resection of the tumor should focus on safe and complete resection and should be en bloc when possible, given the variable metastatic and malignant potential of the tumor.

---

**REFERENCES**


---

**Disclosure forms** provided by the authors are available with the full text and PDF of this article at www.ajnr.org.


